



Press release

Ruelzheim, April 2020

HWI expands with a new location and extends its range of services

Pharmaceutical service provider takes over Frankfurt development site of Losan Pharma

New location, expanded product range, further skilled employees: The HWI group, headquartered in Ruelzheim, is taking over the Frankfurt development site of Losan Pharma GmbH from Neuenburg in southern Baden on April 1st. HWI is thus further developing its strategy in the direction of high potent active ingredients and sterile dosage forms. The location for product development in Frankfurt's Oberhafen industrial area ideally complements HWI's portfolio. HWI is taking over the highly qualified staff as well as the complete equipment with clean rooms, manufacturing equipment and analytical devices.

"With the Frankfurt site we have gained not only qualified experts but also an innovative development location with a functioning infrastructure, with the opportunity to start our work immediately", says HWI Managing Director Dr. Stefan Wissel. "And we are increasing our staff, three HWI employees are already strengthening the Frankfurt team, with others to follow. State-of-the-art isolator technology enables HWI to process high potent active ingredients safely.

The decision for the location takes into account the fact that there are only a few facilities in Europe that can process high potent active ingredients. On the other hand, the demand for active ingredients with high potency will increase in the future. In addition, HWI will in future



be able to develop sterile drugs at the new site, which are subject to particularly high purity and quality requirements. Dr. Stefan Wissel: "We see the HWI site in Frankfurt as a highly developable investment in our future".

The HWI group is a medium-sized, internationally operating company group headquartered in Ruelzheim (southern Palatinate), founded in 1991 and providing services to the pharmaceutical industry in the areas of development, testing, regulatory affairs, vigilance and quality management of drug products and medical devices. The HWI group employs about 200 people at four locations, about 100 of them in Ruelzheim.

The seller of the Frankfurt site is the pharmaceutical technology company Losan Pharma GmbH, Neuenburg, which is specialized in the development and production of innovative drug forms since 1992 and employs 560 people. In addition to the core technologies for the production of pellets, granulates, effervescent tablets, stick packs, liquids and suppositories, Losan Pharma GmbH offers development services for the stabilization of sensitive active ingredients, for the controlled release of active ingredients and for increasing bioavailability using multiparticulate or otherwise sophisticated systems, including nano-formulations, HME technologies and silica-amorphous embeddings. The products developed and manufactured by Losan Pharma GmbH are marketed in more than 70 countries, including the USA, Brazil, Russia, Turkey and China. "Due to the large number of conventional projects and the investments in development and production at the Neuenburg and Eschbach sites necessary for their realisation, we have decided for strategic reasons to sell the Frankfurt site and thus against the further processing of high potent active substances," explained the managing directors of Losan Pharma GmbH, Dr. Jens Morgenthaler and Dr. Thomas Andresen.

Information about HWI under www.hwi-group.de and Losan Pharma under www.losan.de



Picture caption

Highest security level at the Frankfurt site of HWI pharma services GmbH: High potent active ingredients up to OEB 5 can be processed in state-of-the-art isolators.

Press contact

Nadine Lirtz

HWI pharma services GmbH | Rheinzaberner Str. 8 | 76761 Ruelzheim
Phone: +49 7272 7767-2564 | Email: n.lirtz@hwi-group.de | www.hwi-group.de